🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
13/04/2015 0,5100 USD
13/01/2015 0,4900 USD
10/10/2014 0,4200 USD
11/07/2014 0,4200 USD
11/04/2014 0,4200 USD
13/01/2014 0,4000 USD
10/10/2013 0,4000 USD
11/07/2013 0,4000 USD
11/04/2013 0,4000 USD
11/01/2013 0,4000 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/01/2024 161,16 163,66 161,00 163,30 +0,78% 1,65% 5.074.300
17/01/2024 161,75 162,95 161,52 162,04 +0,35% 0,88% 4.423.100
16/01/2024 161,98 162,30 161,02 161,48 -0,57% 0,79% 4.747.700
12/01/2024 162,75 163,30 162,18 162,40 -0,84% 0,69% 4.971.400
11/01/2024 164,25 165,12 163,09 163,78 -0,67% 1,24% 4.591.500
10/01/2024 162,27 165,08 161,88 164,89 +1,59% 1,97% 6.609.900
09/01/2024 161,43 163,47 160,84 162,31 +0,55% 1,63% 4.454.000
08/01/2024 162,18 162,77 159,78 161,43 -0,44% 1,84% 6.001.600
05/01/2024 161,33 163,03 160,61 162,14 +0,42% 1,50% 5.607.600
04/01/2024 160,31 162,29 159,43 161,46 +0,62% 1,78% 8.332.200
03/01/2024 160,59 161,75 159,84 160,46 +0,40% 1,19% 5.301.400
02/01/2024 154,90 160,14 154,77 159,82 +3,13% 3,47% 8.059.900
29/12/2023 154,54 155,21 154,41 154,97 +0,14% 0,52% 3.712.000
28/12/2023 155,25 155,63 154,54 154,75 -0,08% 0,70% 2.601.200
27/12/2023 154,05 154,97 153,72 154,88 +0,17% 0,81% 3.747.400
26/12/2023 154,25 155,28 154,13 154,62 -0,21% 0,75% 2.073.400
22/12/2023 153,29 155,46 153,09 154,94 +1,54% 1,55% 3.373.400
21/12/2023 152,05 152,91 151,29 152,59 +0,59% 1,07% 4.036.100
20/12/2023 153,99 154,21 151,54 151,69 -1,24% 1,73% 4.716.400
19/12/2023 153,59 154,48 152,45 153,60 +0,12% 1,32% 5.476.700
18/12/2023 153,00 154,35 151,75 153,42 -0,40% 1,70% 5.379.600
15/12/2023 154,74 155,89 153,11 154,04 -0,54% 1,80% 15.203.000
14/12/2023 154,36 155,16 152,76 154,88 +0,38% 1,55% 7.869.600
13/12/2023 152,98 154,77 152,73 154,30 +0,69% 1,33% 8.104.500
12/12/2023 151,73 153,59 150,17 153,24 +1,32% 2,25% 5.882.200
11/12/2023 150,67 152,71 150,64 151,24 +1,31% 1,37% 6.343.500
08/12/2023 148,07 150,07 148,00 149,28 +0,89% 1,40% 5.695.200
07/12/2023 147,64 148,38 145,20 147,97 +1,09% 2,15% 7.225.100
06/12/2023 144,79 147,07 144,73 146,38 +1,25% 1,62% 4.978.800
05/12/2023 144,11 145,08 142,66 144,57 +0,29% 1,68% 3.961.700